Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
Results from a University of Pittsburgh study evaluating intensity modulated radiation therapy (IMRT) for head and neck cancer determined the ideal doses for lessening treatment side effects. The findings were presented today at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Denver.
Few treatment options exist for patients with head and neck cancers who develop a second tumor or whose disease recurs in an area that has previously received radiation. Data from an international study reveal a possible new combination treatment regimen that offers a significant survival advantage for many of these patients.
"Patients often experience a great deal of pain if their cancer spreads to the bone," explained Andre Konski, M.D., M.B.A., M.A., F.A.C.R., director of clinical research in the radiation oncology department at Fox Chase Cancer Center and lead author of the paper on the Radiation Therapy Oncology Group study (RTOG 97-14).
Prostate cancer is the second leading cause of death among American men. It is estimated that one in six males will develop the disease during his lifetime. However, promising new treatment options have been developed to help combat this threatening disease.
New research shows that a small gene variation that increases the risk of inherited cancer can also arise during the development of spontaneous, or non-inherited, tumors.
A relatively common cancer susceptibility gene appears to be frequently acquired in metastatic lesions from colorectal cancer, and give cancer cells a growth advantage, according to a study in the October 5 issue of JAMA: The Journal of the American Medical Association.
Tumours that have low concentrations of oxygen (hypoxia) are resistant to radiotherapy. A drug called nimorazole (a hypoxia radiosensitiser) can improve the outcome of radiotherapy for patients with these types of tumours. However, at the moment there is no way to identify people with tumours that lack oxygen, who need this additional drug treatment, from those that only need radiotherapy.
"PET/CT is very helpful in determining where we should pinpoint our biopsies for recurrent disease," said Dr. Carol Shores, assistant professor of otolaryngology/head and neck surgery at UNC and the report's senior author. Shores is a member of the UNC Lineberger Comprehensive Cancer Center.
University of Michigan researchers have figured out one more component in cancer cells' aggressive growth - and hope that knowledge can help kill the cells.
The findings, which appear in the July issue of the journal Molecular Cancer Therapeutics, could lead to a treatment that provides an effective option to surgically removing the cancer, helping patients preserve vital organs involved in speech and swallowing.
A bioadhesive tablet containing the antifungal drug miconazole is an effective and convenient means of treating oropharyngeal candidiasis, which is the most frequently occurring infection in head and neck cancer patients undergoing radiation therapy, scientists reported at the 2nd ESMO Scientific & Educational Conference (ESEC) in Budapest, Hungary.
Adding a third drug to a standard chemotherapy combination can dramatically improve the survival of patients with advanced head and neck cancer, according to research at Dana-Farber Cancer Institute in Boston.
For patients with cancer of the mouth and throat, surgery is a frequent course of treatment, often leading to speech and swallowing dysfunction and external scarring.
The trial, which opened last September, offers research subjects who qualify a new, targeted therapy in addition to standard immune therapy. The drug combination is being studied in a national Phase II clinical trial led by OHSU Cancer Institute researcher Christopher Ryan, M.D., through the Southwest Oncology Group, one of the largest clinical trial cooperative groups in the United States.
The American Society for Therapeutic Radiology and Oncology’s public awareness campaign to educate cancer patients on their treatment options has won an Award of Distinction from The Communicator Awards in their 2005 Print Media competition. ASTRO also received Awards of Distinction for its quarterly magazine, ASTROnews, and its Annual Meeting Guide magazine supplement.
The findings, which will be presented Tuesday, April 19, at the American Association for Cancer Research annual meeting, could lead to a treatment that provides an effective option to surgically removing the cancer, helping patients preserve vital organs involved in speech and swallowing.
Taking high-dose vitamin E supplements for an extended period doesn't protect against cancer; in fact, it may even speed up the development of latent cancers, according to a study by researchers from Hotel-Dieu de Quebec Research Centre and Universite Laval. Their results are published in the April issue of the prestigious Journal of the National Cancer Institute.
A special type of MRI scan that measures the flow of water molecules through the brain can help doctors determine early in the course of brain cancer regimen if a patient's tumor will shrink, a new study shows.
To help cancer patients and their families better understand their treatment options before making a decision, the American Society for Therapeutic Radiology and Oncology has published seven patient information brochures that explain how radiation therapy is used to safely and effectively treat various cancers.
Combination treatment using the monoclonal antibody cetuximab, along with high dose radiotherapy in the treatment of patients with loco-regionally advanced squamous cell carcinoma of the head and neck results in significant improvements in both loco-regional control and overall survival, according to Dr Jordi Giralt of Val d'Hebron University Hospital.